{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:32:01Z","timestamp":1791199921636,"version":"4.2.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Short-term use of pemafibrate (PEM), a selective modulator of peroxisome proliferator-activated receptor alpha, has been reported to improve abnormal liver function in patients with nonalcoholic fatty liver disease with hypertriglyceridemia (HTG-NAFLD). This study aimed to clarify the effects and predictive factors of long-term 72-week PEM administration on body composition, and laboratory tests in HTG-NAFLD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fifty-three HTG-NAFLD patients receiving a 72-week PEM regimen were retrospectively enrolled. Routine blood and body composition results were analyzed immediately before and at the end of the study period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PEM treatment significantly improved liver enzyme levels such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and gamma-glutamyl transferase, along with lipid profiles including triglyceride, total cholesterol, and low-density lipoprotein cholesterol. PEM did not have any detectable impact on body composition parameters. The factors of female, higher AST (\u2265 46 U\/L) and fat mass (\u2265 31.9%), as well as lower soft lean mass (&amp;lt; 61.6%), skeletal muscle mass (&amp;lt; 36%), and skeletal muscle mass index (&amp;lt; 6.9 kg\/m<jats:sup>2<\/jats:sup>) were significantly associated with the treatment response status of a &amp;gt; 30% decrease in ALT. All patients completed the treatment without any adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long-term PEM treatment had a positive impact on liver enzymes and lipid profiles, but it did not result in significant changes in body composition among HTG-NAFLD patients. In predicting the response to PEM treatment, the evaluation of AST and body composition may be useful.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1329294","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T04:19:51Z","timestamp":1715919591000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD"],"prefix":"10.3389","volume":"15","author":[{"given":"Takanobu","family":"Iwadare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kunimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Ichi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeji","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27839","article-title":"Hepatic lipid droplet biology: Getting to the root of fatty liver","volume":"62","author":"Mashek","year":"2015","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic landscape for NAFLD in 2020","volume":"158","author":"Neuschwander-Tetri","year":"2020","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5551\/jat.28720","article-title":"Transcriptome analysis of K-877 (a novel selective PPAR\u03b1 modulator (SPPARM\u03b1))-regulated genes in primary human hepatocytes and the mouse liver","volume":"22","author":"Raza-Iqbal","year":"2015","journal-title":"J Atheroscl Thromb"},{"key":"B6","doi-asserted-by":"publisher","first-page":"42477","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12072-022-10453-1","article-title":"Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study","volume":"17","author":"Morishita","year":"2022","journal-title":"Hepatol Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19072148","article-title":"The Peroxisome Proliferator-Activated Receptor alpha (PPARalpha) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice","volume":"19","author":"Araki","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071667","article-title":"Clinically relevant dose of pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), lowers serum triglyceride levels by targeting hepatic PPARalpha in mice","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomedicines"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/biomedicines10112806","article-title":"Higher responsiveness for women, high transaminase levels, and fat percentage to pemafibrate treatment for NAFLD","volume":"10","author":"Iwadare","year":"2022","journal-title":"Biomed"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12456","article-title":"Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in J apanese patients","volume":"45","author":"Seko","year":"2015","journal-title":"Hepatol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1073025","article-title":"Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients","volume":"10","author":"Sugimoto","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5551\/jat.15792","article-title":"Diagnostic criteria for dyslipidemia executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan\u20142012 version","volume":"20","author":"Teramoto","year":"2013","journal-title":"J Atheroscl Thromb"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2014.12.011","article-title":"Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPAR\u03b1","volume":"1852","author":"Komatsu","year":"2015","journal-title":"Biochim Biophys Acta (BBA)-Mol Basis Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertension Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","article-title":"Japanese clinical practice guideline for diabetes 2019","volume":"11","author":"Araki","year":"2020","journal-title":"Diabetol Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6346(00)00074-7","article-title":"Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data","volume":"18","author":"Ikeda","year":"2000","journal-title":"Hepatol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1527-3350","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.01.002","article-title":"Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: A multicenter registry-based cohort study","volume":"21","author":"Fujii","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3748\/wjg.v22.i4.1664","article-title":"Mechanisms of intrahepatic triglyceride accumulation","volume":"22","author":"Ress","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/nu7115475","article-title":"The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis","volume":"7","author":"Saponaro","year":"2015","journal-title":"Nutrients"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2021.106864","article-title":"Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study","volume":"7","author":"Shinozaki","year":"2021","journal-title":"Clin Exp Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Alimentary Pharmacol Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/jgh.16222","article-title":"Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease","volume":"38","author":"Takahashi","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.2248-23","article-title":"A Comparison of alanine aminotransferase normalization between pemafibrate and bezafibrate in patients with nonalcoholic fatty liver disease","volume":"63","author":"Yamada-Shimizu","year":"2024","journal-title":"Intern Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1329294\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T04:19:54Z","timestamp":1715919594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1329294\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":27,"alternative-id":["10.3389\/fendo.2024.1329294"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1329294","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"article-number":"1329294"}}